Convergence between bone and energy homeostases: Leptin regulation of bone mass

Cell Metabolism

Volumn 4, Issue 5, 2006, Pages 341-348

  Karsenty, Gerard ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEPTIN;

BODY WEIGHT; BONE MASS; BONE REMODELING; ENDOCRINE FUNCTION; ENERGY METABOLISM; GENETIC ANALYSIS; HOMEOSTASIS; HUMAN; HYPOTHALAMUS; HYPOTHESIS; MOLECULAR BIOLOGY; NONHUMAN; OBESITY; OSSIFICATION; OSTEOBLAST; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; REPRODUCTION; REVIEW; SYMPATHETIC TONE; WEIGHT CONTROL;

BONE AND BONES; BONE REMODELING; BONE RESORPTION; ENERGY METABOLISM; HOMEOSTASIS; HUMANS; LEPTIN;

EID: 33750453786     PISSN: 15504131     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cmet.2006.10.008     Document Type: Review

References (50)

1. Ahima R.S. Body fat, leptin, and hypothalamic amenorrhea. N. Engl. J. Med. 351 (2004) 959-962
2. Ahima R.S., Saper C.B., Flier J.S., and Elmquist J.K. Leptin regulation of neuroendocrine systems. Front. Neuroendocrinol. 21 (2000) 263-307
3. Ahn J.D., Dubern B., Lubrano-Berthelier C., Clement K., and Karsenty G. Cart overexpression is the only identifiable cause of high bone mass in Mc4R deficiency. Endocrinology (2006) in press
4. Asnicar M.A., Smith D.P., Yang D.D., Heiman M.L., Fox N., Chen Y.F., Hsiung H.M., and Koster A. Absence of cocaine- and amphetamine-regulated transcript results in obesity in mice fed a high caloric diet. Endocrinology 142 (2001) 4394-4400
5. Bray G.A., and York D.A. The MONA LISA hypothesis in the time of leptin. Recent Prog. Horm. Res. 53 (1998) 95-117
6. Chruscinski A.J., Rohrer D.K., Schauble E., Desai K.H., Bernstein D., and Kobilka B.K. Targeted disruption of the beta2 adrenergic receptor gene. J. Biol. Chem. 274 (1999) 16694-16700
7. Cooper C., and Melton L.J.I. Magnitude and impact of osteoporosis and fractures. In: Marcus R., Feldman D., and Kelsey J. (Eds). Osteoporosis (1996), Academic Press, San Diego 419-434
8. Cornish J., Callon K.E., Bava U., Lin C., Naot D., Hill B.L., Grey A.B., Broom N., Myers D.E., Nicholson G.C., and Reid I.R. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J. Endocrinol. 175 (2002) 405-415
9. Corral D.A., Amling M., Priemel M., Loyer E., Fuchs S., Ducy P., Baron R., and Karsenty G. Dissociation between bone resorption and bone formation in osteopenic transgenic mice. Proc. Natl. Acad. Sci. USA 95 (1998) 13835-13840
10. Dhillon H., Zigman J.M., Ye C., Lee C.E., McGovern R.A., Tang V., Kenny C.D., Christiansen L.M., White R.D., Edelstein E.A., et al. Leptin directly activates SF1 neurons in the VMH, and this action by leptin is required for normal body-weight homeostasis. Neuron 49 (2006) 191-203
11. Ducy P., Amling M., Takeda S., Priemel M., Schilling A.F., Beil F.T., Shen J., Vinson C., Rueger J.M., and Karsenty G. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100 (2000) 197-207
12. Elefteriou F., Ahn J.D., Takeda S., Starbuck M., Yang X., Liu X., Kondo H., Richards W.G., Bannon T.W., Noda M., et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434 (2005) 514-520
13. Elefteriou F., Takeda S., Ebihara K., Magre J., Patano N., Kim C.A., Ogawa Y., Liu X., Ware S.M., Craigen W.J., et al. Serum leptin level is a regulator of bone mass. Proc. Natl. Acad. Sci. USA 101 (2004) 3258-3263
14. Elias C.F., Lee C., Kelly J., Aschkenasi C., Ahima R.S., Couceyro P.R., Kuhar M.J., Saper C.B., and Elmquist J.K. Leptin activates hypothalamic CART neurons projecting to the spinal cord. Neuron 21 (1998) 1375-1385
15. Farooqi I.S., Yeo G.S., Keogh J.M., Aminian S., Jebb S.A., Butler G., Cheetham T., and O'Rahilly S. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J. Clin. Invest. 106 (2000) 271-279
16. Fu L., Patel M.S., Bradley A., Wagner E.F., and Karsenty G. The molecular clock mediates leptin-regulated bone formation. Cell 122 (2005) 803-815
17. Guerardel A., Tanko L.B., Boutin P., Christiansen C., and Froguel P. Obesity susceptibility CART gene polymorphism contributes to bone remodeling in postmenopausal women. Osteoporos. Int. 17 (2006) 156-157
18. Gundberg C.M., Markowitz M.E., Mizruchi M., and Rosen J.F. Osteocalcin in human serum: a circadian rhythm. J. Clin. Endocrinol. Metab. 60 (1985) 736-739
19. Huszar D., Lynch C.A., Fairchild-Huntress V., Dunmore J.H., Fang Q., Berkemeier L.R., Gu W., Kesterson R.A., Boston B.A., Cone R.D., et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88 (1997) 131-141
20. Jochum W., Passegue E., and Wagner E.F. AP-1 in mouse development and tumorigenesis. Oncogene 20 (2001) 2401-2412
21. Karsenty G., and Wagner E.F. Reaching a genetic and molecular understanding of skeletal development. Dev. Cell 2 (2002) 389-406
22. Kristensen P., Judge M.E., Thim L., Ribel U., Christjansen K.N., Wulff B.S., Clausen J.T., Jensen P.B., Madsen O.D., Vrang N., et al. Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 393 (1998) 72-76
23. Kurvers H.A. Reflex sympathetic dystrophy: facts and hypotheses. Vasc. Med. 3 (1998) 207-214
24. Lowrey P.L., and Takahashi J.S. Mammalian circadian biology: elucidating genome-wide levels of temporal organization. Annu. Rev. Genomics Hum. Genet. 5 (2004) 407-441
25. Martin A., de Vittoris R., David V., Moraes R., Begeot M., Lafage-Proust M.H., Alexandre C., Vico L., and Thomas T. Leptin modulates both resorption and formation while preventing disuse-induced bone loss in tail-suspended female rats. Endocrinology 146 (2005) 3652-3659
26. Morse D., and Sassone-Corsi P. Time after time: inputs to and outputs from the mammalian circadian oscillators. Trends Neurosci. 25 (2002) 632-637
27. Okamura H., Miyake S., Sumi Y., Yamaguchi S., Yasui A., Muijtjens M., Hoeijmakers J.H., and van der Horst G.T. Photic induction of mPer1 and mPer2 in cry-deficient mice lacking a biological clock. Science 286 (1999) 2531-2534
28. Olsen B.J., Reginato A.M., and Wang W. Bone Development. Annu. Rev. Cell Dev. Biol. 16 (2000) 191-220
29. Pasco J.A., Henry M.J., Sanders K.M., Kotowicz M.A., Seeman E., and Nicholson G.C. Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J. Bone Miner. Res. 19 (2004) 19-24
30. Perreau-Lenz S., Pevet P., Buijs R.M., and Kalsbeek A. The biological clock: the bodyguard of temporal homeostasis. Chronobiol. Int. 21 (2004) 1-25
31. Potts J.T., and Juppner H. Parathyroid hormone and parathyroid hormone-related peptide in calcium homeostasis, bone metabolism and bone development: the proteins, their genes and receptors. In: Press A. (Ed). Metabolic Bone Disease and Clinically Related Disorders (1998), Academic Press, San Diego 52-94
32. Raisz L.G. Clinical practice. Screening for osteoporosis. N. Engl. J. Med. 353 (2005) 164-171
33. Rejnmark L., Vestergaard P., and Mosekilde L. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J. Hypertens. 24 (2006) 581-589
34. Reppert S.M., and Weaver D.R. Coordination of circadian timing in mammals. Nature 418 (2002) 935-941
35. Riggs B.L., Khosla S., and Melton III L.J. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J. Bone Miner. Res. 13 (1998) 763-773
36. Riggs B.L., and Melton III L.J. Involutional osteoporosis. N. Engl. J. Med. 314 (1986) 1676-1686
37. Rodan G.A., and Martin T.J. Therapeutic approaches to bone diseases. Science 289 (2000) 1508-1514
38. Schibler U., and Naef F. Cellular oscillators: rhythmic gene expression and metabolism. Curr. Opin. Cell Biol. 17 (2005) 223-229
39. Schlienger R.G., Kraenzlin M.E., Jick S.S., and Meier C.R. Use of beta-blockers and risk of fractures. JAMA 292 (2004) 1326-1332
40. Simmons D.J., and Nichols Jr. G. Diurnal periodicity in the metabolic activity of bone tissue. Am. J. Physiol. 210 (1966) 411-418
41. Spiegelman B.M., and Flier J.S. Obesity and the regulation of energy balance. Cell 104 (2001) 531-543
42. Takeda S., Elefteriou F., Levasseur R., Liu X., Zhao L., Parker K.L., Armstrong D., Ducy P., and Karsenty G. Leptin regulates bone formation via the sympathetic nervous system. Cell 111 (2002) 305-317
43. Tartaglia L.A., Dembski M., Weng X., Deng N., Culpepper J., Devos R., Richards G.J., Campfield L.A., Clark F.T., Deeds J., et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 83 (1995) 1263-1271
44. Teitelbaum S.L., and Ross F.P. Genetic regulation of osteoclast development and function. Nat. Rev. Genet. 4 (2003) 638-649
45. Thomas S.A., and Palmiter R.D. Impaired maternal behavior in mice lacking norepinephrine and epinephrine. Cell 91 (1997) 583-592
46. Thomas T., Gori F., Khosla S., Jensen M.D., Burguera B., and Riggs B.L. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 140 (1999) 1630-1638
47. Turker S., Karatosun V., and Gunal I. Beta-blockers increase bone mineral density. Clin. Orthop. Relat. Res. 443 (2006) 73-74
48. Vaisse C., Clement K., Guy-Grand B., and Froguel P. A frameshift mutation in human MC4R is associated with a dominant form of obesity. Nat. Genet. 20 (1998) 113-114
49. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., and Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 372 (1994) 425-432
50. Zheng B., Albrecht U., Kaasik K., Sage M., Lu W., Vaishnav S., Li Q., Sun Z.S., Eichele G., Bradley A., and Lee C.C. Nonredundant roles of the mPer1 and mPer2 genes in the mammalian circadian clock. Cell 105 (2001) 683-694